1. A method of treating inflammation mediated by a cannabinoid receptor comprising contacting said receptor with a compound in an amount to treat said cannabinoid receptor-mediated disorder, wherein the compound is of the formula
wherein
—– represents an optional double bond wherein the ring that optionally contains it is selected from hexahydro, 6a,10a-dehydro, 8,9-dehydro, and 9,10-dehydro;
Y is selected from S, O, CH2, CH(CH3), CH(OH), C(CH3)(OH), C(CH3)2, C(\u2014U(CH2)nU\u2014), C(O), NH, S(O), and S(O)2;
n is an integer\u22671;
U is selected from CH2, S, and O;
Z is selected from H, substituted and unsubstituted alkyl, and
cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, and heterocycloalkylalkyl, wherein each alkyl portion is optionally substituted and the ring portion of each is optionally substituted with one, two, three, four or five substituents; and
R1 is selected from H and substituted and unsubstituted alkyl.
2. A method according to claim 1 wherein
R1 is selected from H and alkyl;
Y is selected from carbonyl, dimethylmethylene and hydroxymethylene; and
Z is selected from substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted phenyl, and substituted or unsubstituted thiophenyl.
3. A method according to claim 2 wherein Z is alkyl, cycloalkyl, phenyl or thiophenyl.
4. A method according to claim 3 wherein Z is hexyl, cyclohexyl, phenyl or thiophenyl.
5. A method according to claim 2 wherein Y is dimethylmethylene.
6. A method according to claim 2 wherein the ring having —– is hexahydro or 6a,10a-dehydro.
7. A method according to claim 1 wherein the compound is selected from
a) 3-Benzyl-6,6,9-trimethyl-6a,7,8,9,10,10a-hexahydro-6H-isochromeno3,4-dpyrimidin-1-ol;
b) (6aS,9R,10aR)-6,6,9-Trimethyl-3-(2-methyloctan-2-yl)-6a,7,8,9,10,10a-hexahydro-6H-isochromeno3,4-dpyrimidin-1-ol;
c) (6aS,9R,10aR)-6,6,9-trimethyl-3-(2-phenylpropan-2-yl)-6a,7,8,9,10,10a-hexahydro-6H-isochromeno3,4-dpyrimidin-1-ol;
d) (6aS,9R,10aR)-3-(2-Cyclohexylpropan-2-yl)-6,6,9-trimethyl-6a,7,8,9,10,10a-hexahydro-6H-isochromeno3,4-dpyrimidin-1-ol;
e) (6aS,9R,10aR)-6,6,9-Trimethyl-3-(2-(thiophen-2-yl)propan-2-yl)-6a,7,8,9,10,10a-hexahydro-6H-isochromeno3,4-dpyrimidin-1-ol;
f) (6aR,9S,10aS)-6,6,9-Trimethyl-3-(2-phenylpropan-2-yl)-6a,7,8,9,10,10a-hexahydro-6H-isochromeno3,4-dpyrimidin-1-ol;
g) 3-Benzyl-6,6,9-trimethyl-tetrahydro-6H-isochromeno3,4-dpyrimidin-1-ol; and
h) 3-Benzyl-6,6,9-trimethyl-7,8,9,10-tetrahydro-6H-isochromeno3,4-dpyrimidin-1-ol.
8. A method according to claim 1 wherein the cannabinoid receptor is selected from CB-1 and CB-2.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A battery comprising:
an anode comprising anode material in contact with a metal anode current collector;
a cathode comprising cathode material in contact with a cathode current collector comprising a transparent conducting oxide (TCO); and
an electrolyte with a pH in a range of 3 to 7.
2. The battery of claim 1, wherein the transparent conducting oxide (TCO) comprises one or more of the following: indium tin oxide (ITO), indium zinc oxide (IZO), Al-doped zinc oxide (AZO), and Ga-doped zinc oxide (GZO).
3. The battery of claim 1, wherein the cathode material is MnO2.
4. The battery of claim 1, wherein the electrolyte is an aqueous solution.
5. The battery of claim 1, wherein the electrolyte is a gel.
6. The battery of claim 1, wherein the electrolyte comprises one or more of the following: zinc chloride, zinc acetate, and ammonium chloride.
7. The battery of claim 1, wherein the battery has a volume less than 1 cubic mm.
8. The battery of claim 1, wherein a thickness of the cathode current collector is in a range of 20 nm to 200 nm.
9. The battery of claim 1, wherein the battery has a flexibility defined by a radius of curvature of between about 4 mm and about 20 mm.
10. The battery of claim 1, wherein the battery has a thickness of less than about 150 microns.
11. The battery of claim 1, wherein the battery has an open circuit voltage of between 1.4V and 1.8V and has a discharge capacity of between 10 uA-hours and 200 uA-hours.
12. The battery of claim 1, wherein the cathode material is one or more of the following: electroplated nickel hydroxide; and a mixture of MnO2, with or without binder.
13. The battery of claim 1, wherein the anode material is electroplated Zn on the current collector that comprises one or more of the following: Sn, In, Ni, and an alloy such as brass or bronze.
14. The battery of claim 1, wherein the battery has a shape of an arc.
15. The battery of claim 1, wherein a potential for an onset of hydrogen evolution as measured on a cyclic voltammetry curve is less than \u22121.6V relative to HgHgO for a KOH solution.
16. A method for forming a battery, the method comprising the steps of:
fabricating a cathode in a first cavity in a first dielectric element;
fabricating an anode in a second cavity in a second dielectric element; and
joining the cathode and the anode in a complanate manner.
17. The method of claim 16, wherein the step of fabricating the cathode comprises the use of no more than two lithographic masks.
18. The method of claim 16, wherein the step of fabricating the anode comprises the use of no more than three lithographic masks.
19. The method of claim 16, wherein the step of fabricating the battery comprises the use of subtractive photolithographic techniques.
20. The method of claim 16, wherein the first cavity and the second cavity are etched using laser processing.